21/04/2017 12:20:00

Participate in our $3 million Private Placement to Earn a Potential 20% Return on Investment in THC Therapeutics (THCT) Stock

LAS VEGAS, April 21, 2017 (GLOBE NEWSWIRE) -- THC Therapeutics (THCT) is offering a Reg D private placement to accredited investors, through which we will raise up to $3,000,000. Proceeds from this offering will start the process for THC Therapeutics to become a fully reporting company to the SEC. 50% of the money raised will go towards mergers and acquisitions, the other half will go toward general business operating expenses. This offering will be good for our company, current shareholders and new investors. An example of the terms is as follows, for a $100,000 investment in this private placement, the investor will receive $120,000 of common stock 1 year from the date of investment. The price per share will be determined by the market value at the time the common stock will be issued. This correlates to a 20% return on investment. Minimum investment is $25,000. Prior to investing, all investors must verify their accredited status. No offering is made to any person who does not meet the definition of an accredited investor under Rule 501(a). Further information is contained in our private placement memorandum, which should be reviewed in full before making a decision to invest.

Visit our website to participate in THC Therapeutics Private Placement. (http://thctherapeutics.com/)

Comments from Brandon Romanek, Founder & CEO, “Because of my vast experience as a trader, investor and portfolio manager, I have come up with a creative strategy where one can make a potential 20% return on investment. This will be great for THC Therapeutics, our current shareholders and investors in this offering. I am not willing to sell shares at a discount in an offering like this anywhere near our current stock price. Most of these types of offerings are priced below market value. Investors would have to hold for one year and this could present substantial risk to the investor. That structure does not work at all for THC Therapeutics. When a company does that, it makes a statement of what they believe their current stock price should be and that they’re willing to raise money at a significant discount to market. I am now in the process of returning 1.8 Million shares of my stock in THCT back into the company’s treasury. I am doing this to limit any dilution that can occur with this offering. I’d be happy to personally answer any questions regarding this private placement. Please call or email me directly at Brandon@thctherapeutics.com. I would like to thank everyone for believing in my vision and I promise to do whatever it takes to make THC Therapeutics a premier Health and Healing Cannabis company.”

About THC Therapeutics:

THC Therapeutics is a forward-thinking publicly traded health and healing company in the cannabis industry that has "Better Health through the Science of Nature" as their mission statement. The company is dedicated to innovating new methods and refining current industry standards in the cannabis market. THC Therapeutics' plans for future growth include cultivation, dispensing, extractions, edibles, personal wellness centers and flotation therapy. For more information, visit THCTherapeutics.com.

Forward-Looking Statements Disclosure:

This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "beliefs," "estimates," "expects," "intends," "plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.

Phone: 702.602.THCC (8422)

Follow Brandon Romanek on Twitter:

Twitter @BrandonRomanek

Follow THC Therapeutics on Facebook and Twitter:

Twitter @THCTherapeutics

Facebook @THCTherapies

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
22 Jan
 
Jeg har idag meldt Roland333 til finanstilsynet for gentagende gange at have overtrådt Artikel 12 st..
69
23 Jan
 
  På den aktuelle liste over BEDST VURDEREDE INDLÆG handler 8 ud af 10 – altså 80% - om at melde hin..
44
18 Jan
OMXC25
@ Poppelkongen: Jeg tror ski da, at du har misforstået brugen af filteret?! Når du nævner, at du er..
37
23 Jan
 
Her til moirgen har jeg fået tilbagemelding fra Finanstylsynet, om at de har oprettet en sag og unde..
31
23 Jan
 
og du er sammen med lpe123 blevet anmeldt til børneværnet. 
31
17 Jan
 
Hej alle,   Nu hvor jeg tager et sabat-år som investor i 2018, tænkte jeg, at jeg ville lave en upda..
26
23 Jan
GEN
Tror ikke der er mange der forventer, at du forstår noget Roland.
25
19 Jan
 
Jeg har på en fornemmelsen at i ikke bryder jer om mig? Ik sandt? Så har overvejet at stoppe på EI. ..
24
23 Jan
 
@roland333,   2 ting!   1.) Du ved ikke engang hvordan man melder en person til finans-tilsynet.    ..
23
20 Jan
 
Jeg stiller mig tvivlende,,,,,: At som dansk at betale til Prins Henrik & Co der skider DK en hatful..
19

Man Group PLC : Form 8.3 - [Intu Properties plc] - Amendment

23/01/2018 14:37:27
Amendment to cash-settled derivatives (50p ordinary) positions, section 2(a). FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: ..

Alliance Trust PLC : Net Asset Value(s)

23/01/2018 13:47:03
ALLIANCE TRUST PLC                                    At the close of business on Monday 22 January 2018: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 814.7p -       including income, 818.7p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inco..

Investec Bank plc : Form 8.5 (EPT/RI) - Melrose Industries plc

23/01/2018 10:51:00
 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18
2
Pirelli BNP Paribas Primary New Issues : Stabilisation Notice
3
Timberland Bancorp Earnings Per Share Increases 12% to $0.48 for First Fiscal Quarter of 2018
4
Klink & Klink Announces Retention by MGP Wealth Management Investors and Sagacious Asset Management for Woodbridge Capital LLC Chapter 11 Restructuring
5
Be Prepared for the May 2018 EU General Data Protection Requirements (GDPR) Deadline with Cost Effective SPYRUS Security Solutions

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 January 2018 01:30:55
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180122.2 - EUROWEB4 - 2018-01-24 02:30:55 - 2018-01-24 01:30:55 - 1000 - Website: OKAY